Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolCVE:ACST
CUSIPN/A
Phone+1-450-6864555
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-162.34%
Return on Assets-103.36%
Miscellaneous
EmployeesN/A
Outstanding Shares25,638,000
Acasti Pharma (CVE:ACST) Frequently Asked Questions
What is Acasti Pharma's stock symbol?
Acasti Pharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ACST."
Who are some of Acasti Pharma's key competitors?
Some companies that are related to Acasti Pharma include Trillium Therapeutics (TRIL), Tiziana Life Sciences (TILS), Bioventix (BVXP), Medicure Inc. Common Stock (MPH), Oncolytics Biotech (ONC), Kitrinor Metals (SCYB), Emblem (EMMBF), Pfenex (PFNX), Oragenics (OGEN), Asterias Biotherapeutics (AST), Promis Neurosciences (PMN), Tissue Regenix Group (TRX), Covalon Technologies (COV), Matinas BioPharma (MTNB) and Motif Bio (MTFB).
Who are Acasti Pharma's key executives?
Acasti Pharma's management team includes the folowing people:
- Ms. Janelle D' Alvise, CEO, Pres & Director
- Ms. Linda P. O'Keefe, CFO & Sec.
- Dr. Pierre Lemieux, Chief Operating Officer
- Mr. Laurent Harvey, VP of Clinical & Non-Clinical Affairs
- Mr. Brian James Groch, Chief Commercial Officer (Age 51)
Has Acasti Pharma been receiving favorable news coverage?
Press coverage about ACST stock has been trending somewhat negative recently, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Acasti Pharma earned a news impact score of -0.02 on Accern's scale. They also assigned press coverage about the company an impact score of 44.30 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Acasti Pharma?
Shares of ACST and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Acasti Pharma's stock price today?
One share of ACST stock can currently be purchased for approximately C$0.94.
How big of a company is Acasti Pharma?
Acasti Pharma has a market capitalization of C$33.54 million.
How can I contact Acasti Pharma?
Acasti Pharma's mailing address is 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada. The company can be reached via phone at +1-450-6864555.
MarketBeat Community Rating for Acasti Pharma (ACST)
MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote "Outperform" if you believe ACST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACST will underperform the S&P 500 over the long term. You may vote once every thirty days.
